The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

The FDA has expanded the approval of Dupixent to include adolescents aged 12 to 17 years with inadequately controlled CRSwNP.

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $29.9 billion by 2032, ...

and has proven useful to delineate the presence of nasal polyps (often hidden from anterior viewing), septal spurs, bifid turbinates and other anatomical disturbances, as well as in localizing the ...

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...

Upstream Bio has become the latest biotech to chance its arm with a public listing in the US, hoping to raise funds for ...

This is different from rhinitis, which is effectively treated by standard-delivery topical medication, and also different from treating nasal polyps, which can sometimes extend down into areas ...

The Business Research Company's Chronic Rhinosinusitis With Nasal Polyps Global market Report 2024 – Market Size, Trends, And Market Forecast 2024-2033 The Business Research Company's Chronic ...

In these trials, XHANCE improved symptoms, sinus opacification, and quality of life in both groups of CRS patients either with or without prior sinus surgery, indicating that previous surgery is not ...